Upadacitinib (Rinvoq®) is indicated for the treatment of moderate-to-severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs. Upadacitinib may be used as monotherapy or in combination with methotrexate.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||29/10/2019|
|Rapid review completed||10/12/2019|
|Rapid Review outcome||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of upadacitinib (Rinvoq®) compared with the current standard of care, on the basis of the proposed price relative to currently available therapies.